Cargando…
Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes?
OBJECTIVE: The aim of this study was to investigate an independent correlation between high sensitivity C-reactive protein (hs-CRP) and glycated haemoglobin (HbA1c) on one side and between hs-CRP and arterial pressure in well glucose controlled type 2 diabetics on the other side. RESULTS: The mean o...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591512/ https://www.ncbi.nlm.nih.gov/pubmed/28886725 http://dx.doi.org/10.1186/s13104-017-2785-4 |
_version_ | 1783262728106803200 |
---|---|
author | Patrice, Nzogang K. Martial, Donkeng J. Bruno, Telefo P. |
author_facet | Patrice, Nzogang K. Martial, Donkeng J. Bruno, Telefo P. |
author_sort | Patrice, Nzogang K. |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to investigate an independent correlation between high sensitivity C-reactive protein (hs-CRP) and glycated haemoglobin (HbA1c) on one side and between hs-CRP and arterial pressure in well glucose controlled type 2 diabetics on the other side. RESULTS: The mean of HbA1c was 6.37% in this study and 70.10% of participants had an HbA1c less than 7%. A positive correlation between hs-CRP and HbA1c was found in the current study (r = 0.232; P = 0.043) and we observed a decrease of 0.79% of HbA1c of the participants when their hs-CRP was less than 1 mg/l compared to that of the participants who had hs-CRP more than 1 mg/l (5.75 ± 1.25% VS 6.54 ± 1.42% P value = 0.04 Student). No correlation was found between hs-CRP and arterial pressure in this study. These results could justify the perspective use of anti-inflammatory drugs in the management of T2D. However the presence of participants with HbA1c levels greater than 7% makes plausible the influence of confounding factors on the observed correlations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13104-017-2785-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5591512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55915122017-09-13 Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? Patrice, Nzogang K. Martial, Donkeng J. Bruno, Telefo P. BMC Res Notes Research Note OBJECTIVE: The aim of this study was to investigate an independent correlation between high sensitivity C-reactive protein (hs-CRP) and glycated haemoglobin (HbA1c) on one side and between hs-CRP and arterial pressure in well glucose controlled type 2 diabetics on the other side. RESULTS: The mean of HbA1c was 6.37% in this study and 70.10% of participants had an HbA1c less than 7%. A positive correlation between hs-CRP and HbA1c was found in the current study (r = 0.232; P = 0.043) and we observed a decrease of 0.79% of HbA1c of the participants when their hs-CRP was less than 1 mg/l compared to that of the participants who had hs-CRP more than 1 mg/l (5.75 ± 1.25% VS 6.54 ± 1.42% P value = 0.04 Student). No correlation was found between hs-CRP and arterial pressure in this study. These results could justify the perspective use of anti-inflammatory drugs in the management of T2D. However the presence of participants with HbA1c levels greater than 7% makes plausible the influence of confounding factors on the observed correlations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13104-017-2785-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-08 /pmc/articles/PMC5591512/ /pubmed/28886725 http://dx.doi.org/10.1186/s13104-017-2785-4 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Note Patrice, Nzogang K. Martial, Donkeng J. Bruno, Telefo P. Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? |
title | Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? |
title_full | Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? |
title_fullStr | Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? |
title_full_unstemmed | Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? |
title_short | Is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? |
title_sort | is it a supplementary benefit to use anti-inflammatory agents in the treatment of type 2 diabetes? |
topic | Research Note |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591512/ https://www.ncbi.nlm.nih.gov/pubmed/28886725 http://dx.doi.org/10.1186/s13104-017-2785-4 |
work_keys_str_mv | AT patricenzogangk isitasupplementarybenefittouseantiinflammatoryagentsinthetreatmentoftype2diabetes AT martialdonkengj isitasupplementarybenefittouseantiinflammatoryagentsinthetreatmentoftype2diabetes AT brunotelefop isitasupplementarybenefittouseantiinflammatoryagentsinthetreatmentoftype2diabetes |